Table 1 Description of study population and anti-hypertensive treatment of the groups
| Â | Population | |||||
|---|---|---|---|---|---|---|
The rest of the screening population | SPA-group | |||||
|  | All (n = 307) | SP (n = 94) | NSP (n = 213) | All (n =46) | SP (n = 28) | NSP (n = 18) |
Female | 164 | 47 | 117 | 18 | 11 | 7 |
Male | 189 | 75 | 114 | 28 | 7 | 21 |
Age (years) | 60.0 ± 11.1 | 56.0 ± 11.9 | 61.8 ± 10.3 | 59.7 ± 10.6 | 56.3 ± 10.8 | 65.1 ± 7.9 |
BMI (kg/m 2 ) | 28.7 ± 4.5 | 28.4 ± 5.2 | 28.8 ± 4.2 | 29.0 ± 4.2 | 28.6 ± 3.8 | 29.6 ± 4.7 |
Mean SBP (mmHg) | 146.9 ± 21.0 | 149.9 ± 22.3 | 145.6 ± 20.4 | 152.0 ± 20.9 | 152.2 ± 20.9 | 152.7 ± 21.5 |
Mean DBP(mmHg | 86.8 ± 10.6 | 87.5 ± 10.5 | 86.4 ± 10.7 | 91.0 ± 9.0 | 91.0 ± 8.1 | 90.9 ± 10.5 |
Duration of HT (years) | 12.6 ± 9.8 | 13.1 ± 9.3 | 12.3 ± 10.1 | 12.9 ± 6.9 | 12.9 ± 5.6 | 12.8 ± 8.8 |
No of drugs* | 1.8 ± 1.1 | 2.3 ± 1.3 | 1.6 ± 0.9 | 2.4 ± 1.1 | 2.6 ± 1.3 | 2.1 ± 0.8 |
No of drugs 0 to 3 | 279 | 75 | 204 | 39 | 21 | 18 |
No of drugs 4 to 5 | 26 | 18 | 8 | 7 | 7 | 0 |
β-blockers | 165 | 60 | 105 | 34 | 22 | 12 |
ACE – & AII-inhibitors | 154 | 60 | 94 | 24 | 16 | 8 |
diuretics | 131 | 47 | 84 | 18 | 13 | 5 |
Spironolactone | 0 | 0 | 0 | 2 | 2 | 0 |
Potassium supplements | 14 | 8 | 6 | 3 | 3 | 0 |
Serum Potassium (mmol/l) | 4.0 ± 0.4 | 3.9 ± 0.4 | 4.0 ± 0.4 | 3.7 ± 0.3 | 3.7 ± 0.5 | 3.7 ± 0.3 |